NCT07237516招募中不适用
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 11
- 主要终点
- Clinical remission as evaluated by the Simple Clinical Colitis Activity Index (SCCAI) for the patient-reported outcomes.
研究概览
简要总结
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, age 18 years or older, with Crohn's disease (CD), ulcerative colitis (UC) or Inflammatory Bowel Disease Unclassified (IBDU), who are either starting Zymfentra at week 10 (IFX-dyyb) in the setting of standard-of-care initiation with intravenous Infliximab (IFX) originator or IFX biosimilars induction therapy at weeks 0,2,6 or switching from intravenous IFX originator or IFX biosimilars during maintenance therapy to Zymfentra (IFX-dyyb)
- •Anticipation that the patient will be followed by the participating center for the next 12 months.
- •3. Diagnosis of CD, UC or IBDU must be established based on standard clinical, radiographic, endoscopic, and histologic criteria as described below.
- •The following diagnostic criteria were developed by the NIDDK IBD Genetics Consortium and are provided as guidelines to complete documentation on individuals with CD, UC or IBDU:
- •A) Symptoms including one or more: diarrhea, rectal bleeding, abdominal pain, fever, complicated perianal disease, extraintestinal manifestations, weight loss or failure to thrive.
- •AND B) Symptoms on two or more occasions separated by at least 8 weeks or ongoing symptoms of at least 6 weeks duration. When there has been a single episode of colitis (in some instances less than 6 weeks duration) resulting in colectomy and resolution of disease symptoms, pathology on the colectomy specimen should be consistent with idiopathic IBD and microbiology studies should be negative.
- •C) One or more of the following providing objective evidence of inflammation:
- •Endoscopic: Mucosal edema, erythema, loss of normal submucosal vasculature, friability, ulceration, stricture formation, pseudopolyps, mucosal edema, erythema. Where there are only minor changes (mucosal edema, erythema, loss of normal submucosal vasculature, friability) mucosal biopsies should have been done to confirm the presence of IBD.
- •Radiologic: Mucosal thickening and/or nodularity, ulceration, stricture, pseudopolyps, fistula formation, pseudosacculation. Minor changes alone (mucosal thickening and/or nodularity) should not be sufficient to make a diagnosis of IBD.
- •Histologic: Mucosal erosion or ulceration, architectural changes of crypts, Paneth cell metaplasia (in colon), transmural inflammatory infiltrate*, fibrosis of muscularis propria*, noncaseating granuloma*.
- •Individuals with IBD should be classified into one of three categories, based on most recent diagnosis:
- •Crohn's disease (CD):
- •Evidence of small intestinal inflammation with endoscopically, radiologically or histologically demonstrated ulcerations, fistulation, mucosal fissuring, nodularity or cobblestoning, stricture formation or histologically demonstrated transmural inflammation with or without granuloma formation.
- •Isolated esophageal, gastric or duodenal inflammation with the finding of noncaseating granuloma.
- •Colonic inflammation which is patchy (normal segments separating areas of inflammation, as described above) or associated with one or more of the following features: complete rectal sparing, multiple (>10) aphthoid ulcers, deep ulceration (into the muscularis propria), transmural inflammation, extensive fibrosis and wall thickening, fistulation, non-caseating granuloma. (N.B. See note below regarding patchiness of endoscopically observed inflammation in patients with partially treated ulcerative colitis.)
- •The presence of complex suppurative perianal disease (i.e. more than a superficial fistula or uncomplicated superficial abscess).
- •If there are fewer than 10 aphthoid ulcers in the cecum (and the rest of the colon appears normal) in a patient with small bowel disease then this should be called small bowel disease only. Similarly, if the colon is normal except for the presence of a fistula extending from inflamed small bowel, the patient should be said to have small bowel disease alone. If the cecum is involved with ulcers larger than aphthoid ulcers or ulcers that are deep or if the involvement has resulted in deformity of the cecum this would be considered to be colonic involvement.
- •Ulcerative Colitis (UC)
- •1) Superficial inflammation and/or ulceration (involving only the mucosa and submucosa) of the colon which is continuous from the rectum extending proximally without skip lesions or complete rectal sparing (N.B. Relative rectal sparing is allowed for patients receiving topical rectal therapy; patchiness of endoscopic inflammation may be observed in patients with partially treated ulcerative colitis).
- •2) In patients with proctitis or left-sided ulcerative colitis there may be an area of inflammation in the cecum, usually surrounding the appendiceal orifice.
- •3) No inflammation of the small intestine ("backwash ileitis" is allowed - non-stricturing superficial inflammation of the terminal ileal mucosa associated with severe pancolitis which resolves following medical or surgical treatment of the colitis).
- •4) No features of Crohn's disease listed above.
- •Inflammatory Bowel Disease Unclassified (IBDU):
- •Confirmed IBD by A, B and C above.
- •Physician unable to classify individual into either CD or UC based on above criteria and/or patient has features of both CD and UC with none of the feature's diagnostic of one or the other.
排除标准
- •Patients will be excluded if they meet any of the following criteria:
- •Inability to provide informed consent.
- •Non-English speaking
- •Patients presenting for a one-time consultation.
结局指标
主要结局
Clinical remission as evaluated by the Simple Clinical Colitis Activity Index (SCCAI) for the patient-reported outcomes.
时间窗: Weeks 0,1, 2, 4, 6,10, 14, 18, 24, 36, and 52.
The SCCAI is a 6-item that describes the symptoms and disease activity of a patient with UC at the time of assessment. A score of 0-4 is considered a clinical range of remission (but with more refined definitions of clinical remission with SCCAI ≤2 and very mild symptoms with a score \>2 ≤4), 5-7 mild activity, 8-16 moderate activity and \> 16 severe activity. A response will be defined as a decrease of the SCCAI score \< 5 points in patients with a baseline SCCAI ≥5.
Clinical remission as evaluated by the Simple Crohn's Disease Activity Index (sCDAI for the patient-reported outcomes.
时间窗: Weeks 0,1, 2, 4, 6,10, 14, 18, 24, 36, and 52
The Short Crohn's Disease Activity Index (sCDAI) is a simplified version of the Crohn's Disease Activity Index (CDAI), used to assess disease severity in Crohn's disease patients. It reduces the number of variables required, making it easier and quicker to use in clinical practice. Recent data demonstrated, that collections of the parameters on a single day equally reflects reliable disease activity compared to a collection of data over 7 consecutive days, which is often hampered by missing data. A score of \< 150, 150-219, 220-450 and \>450 reflects remission, mild, moderate and severe Crohn's disease activity.
次要结局
- Response as measured by the Simple Endoscopic Score for Crohn's disease (SES-CD)(Through study completion, an average of 1 year)
- Response as measured by the endoscopic Mayo score for ulcerative colitis(Through study completion, an average of 1 year)
- Mucosal healing will be assessed in the setting of standard-of-care calprotectin levels.(Weeks 0, 14, 24, and 52.)
- Response as measured by Patient-Reported Outcomes Measurement Information System (PROMIS)- Depression(Weeks 0, 24, and 52.)
- Response as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) -Anxiety Score(Weeks 0, 24, and 52.)
- Response as measured by Patient-Reported Outcomes Measurement Information System (PROMIS) -Social Satisfaction Score(Weeks 0, 24, and 52.)
- Response as measured by Likert scale urgency Score(Weeks 0,1, 2, 4, 6,10, 14, 18, 24, 36, and 52)
- Response as measured by Functional Assessment of Chronic Illness Therapy (FACIT)- Fatigue Scale Score(Weeks 0, 24, and 52)
- Response as measured by The Short Inflammatory Bowel Disease Questionnaire (SIBDQ) score(Weeks 0,4,10,14,18,24,36 and 52.)
- Response as measured by The Work Productivity and Activity Impairment questionnaire (WPAI)(Weeks 0, 24, and 52)
研究者
研究点 (11)
Loading locations...
相似试验
终止
3 期
Zephyrus II：一项评价 pamrevlumab 治疗特发性肺纤维化（IPF）有效性和安全性的 III 期、随机、双盲、安慰剂对照研究CTR2022194640
已完成
早期 1 期
Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis SuppurativaHidradenitis SuppurativaNCT05663268Services Institute of Medical Sciences, Pakistan37
终止
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell ArteritisGiant Cell ArteritisNCT00076726Centocor, Inc.44
已完成
2 期
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related CachexiaCachexiaPancreatic NeoplasmsNCT00060502Centocor, Inc.73
已完成
3 期
Infliximab Plus Methotrexate for the Treatment of Rheumatoid ArthritisRheumatoid ArthritisNCT00269867Centocor, Inc.428